title: [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
abstract: Hand-foot syndrome( HFS) has been reported to be the most common adverse effect of capecitabine, with an incidence of more than 50%. AboundTM, containing β-hydroxy-β-methyl butyric acid( HMB), L-glutamine, and L-arginine is effective in the treatment of decubitus ulcers and in wound healing; however, whether AboundTM is efficacious for HFS caused by capecitabine is not clear. This study aimed at evaluating the effectiveness of AboundTM in the recovery from HFS caused by capecitabine. Capecitabine administration was discontinued in 6 patients with more than grade 2 HFS, and AboundTM was administered. The time to recovery was examined. The median time to recovery to less than grade 1 HFS was 10 days( range, 4-14 days). The grade of HFS decreased following the administration of AboundTM. The findings of this study suggest that AboundTM is effective against HFS caused by capecitabine.
authors.affiliation: Dept. of Pharmacy, Sakai City Hospital.
authors.forename: Chika
authors.initials: C
authors.lastname: Fujii
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Fukunaga
authors.forename: Shunji
authors.initials: S
authors.lastname: Kamigaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Tomono
authors.initials: T
authors.lastname: Kawase
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kawabata
authors.forename: Misako
authors.initials: M
authors.lastname: Fujino
authors.forename: Chihiro
authors.initials: C
authors.lastname: Iseki
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Hamaguchi
authors.forename: Emiko
authors.initials: E
authors.lastname: Yamamoto
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishizaka
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Hachino
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use*; D002087:Butyrates / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005973:Glutamine / Q000627:therapeutic use*; D060831:Hand-Foot Syndrome / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006880:Hydroxy Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy
chemical_list: C586811:Abound vaccine; D000964:Antimetabolites, Antineoplastic; D002087:Butyrates; D006880:Hydroxy Acids; D005973:Glutamine; D003841:Deoxycytidine; D000069287:Capecitabine; D001120:Arginine; D005472:Fluorouracil